BioAge Labs’ (BIOA) Buy Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of BioAge Labs (NASDAQ:BIOA) in a research note released on Tuesday morning,Benzinga reports. The brokerage currently has a $40.00 price objective on the stock.

A number of other equities analysts also recently issued reports on the stock. Jefferies Financial Group set a $21.00 price objective on shares of BioAge Labs in a research note on Friday, July 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, July 21st. Wall Street Zen downgraded BioAge Labs from a “sell” rating to a “strong sell” rating in a report on Saturday, September 5th. Roth Capital reissued a “buy” rating and issued a $25.00 price target on shares of BioAge Labs in a research report on Friday, July 31st. Finally, Needham & Company LLC decreased their price objective on BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, BioAge Labs has an average rating of “Moderate Buy” and a consensus target price of $36.57.

BioAge Labs Price Performance

BIOA stock opened at $8.65 on Tuesday. BioAge Labs has a 1-year low of $4.68 and a 1-year high of $25.95. The business has a 50-day moving average price of $15.26 and a 200 day moving average price of $17.51. The company has a market capitalization of $397.04 million, a P/E ratio of -3.63 and a beta of 0.94.

BioAge Labs (NASDAQ:BIOA) last issued its earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.07. The company had revenue of $2.45 million for the quarter. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. On average, analysts anticipate that BioAge Labs will post -2.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioAge Labs

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its holdings in BioAge Labs by 60.8% in the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock worth $1,873,000 after purchasing an additional 171,426 shares during the last quarter. Walleye Capital LLC purchased a new stake in shares of BioAge Labs during the 2nd quarter valued at $64,000. Marshall Wace LLP lifted its holdings in shares of BioAge Labs by 324.7% during the 2nd quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock valued at $937,000 after purchasing an additional 173,388 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of BioAge Labs by 85.6% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after purchasing an additional 5,976 shares in the last quarter. Finally, Ameriprise Financial Inc. acquired a new stake in shares of BioAge Labs in the 2nd quarter worth $182,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.